A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in Argentina.
Urothelial Carcinoma
DRUG: Atezolizumab
Percentage of Participants with Adverse Events (AE), Up to approximately 2 years.
Percentage of participants with Confirmed Objective Response (ORR) of Complete Response (CR) or Partial Response (PR), Up to approximately 2 years.|Duration of Response (DOR), Up to approximately 2 years.|Progression Free Survival (PFS), Up to approximately 2 years.|Overall Survival (OS), Up to approximately 2 years.
The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in Argentina.